Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
Looking to solidify semaglutide's reign over GLP-1, Novo Nordisk posts key PhII win
Novo Nordisk is one step closer to unlocking a new semaglutide franchise — one it hopes can spur even better results for people with type 2 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
